Journals / Düzce Tıp Fakültesi Dergisi / 2011 / Cilt: 13 - Sayı: 2

The Association Between Microalbuminuria and Carbonmonoxide Diffusion Capacity in Patients with Type-II Diabetes Mellitus

Tip-II Diyabetli Hastalarda Mikroalbüminüri ile Karbonmonoksit Difüzyon Kapasitesi Arasındaki İlişki

Pages
30–35
Publication Date
2011-07-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We found no difference betweenthree groups in terms of DLCO (p=0.947).Conclusion: The results of the study indicate that as microvascular complications(microalbuminuria) develop in the kidneys, possibly no microvascular changes occur in thelungs, if any, the changes do not cause any functional changes in type 2 diabetes mellitus patientsat early stages

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Microalbuminuria is an important indicator of microvascular changes.
📊
Key Findings & Data:Based on these facts, we aimed to evaluate whether any microvascularchanges occur in the lungs before microalbuminuria becomes apparent.Material and Methods: We research carbonmonoxide diffusion capacity (DLCO) in bothnormoalbuminuric and microalbuminuric type 2 diabetes mellitus patients.
💡
Conclusion & Impact:We found no difference betweenthree groups in terms of DLCO (p=0.947).Conclusion: The results of the study indicate that as microvascular complications(microalbuminuria) develop in the kidneys, possibly no microvascular changes occur in thelungs, if any, the changes do not cause any functional changes in type 2 diabetes mellitus patientsat early stages
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Tip 2 diyabet · mikroalbüminüri · normoalbüminüri

Abstract

Aim: Microalbuminuria is an important indicator of microvascular changes. Identifying patientsat this stage is critical, since nephropathy might be at least partly reversible with aggressiveblood glucose control. Based on these facts, we aimed to evaluate whether any microvascularchanges occur in the lungs before microalbuminuria becomes apparent.Material and Methods: We research carbonmonoxide diffusion capacity (DLCO) in bothnormoalbuminuric and microalbuminuric type 2 diabetes mellitus patients. Age and gendermatched 40 microalbuminuric and 40 normoalbuminuric type 2 diabetes mellitus patients, and40 healthy controls were recruited to this study.Results: We evaluated DLCO results among these groups. We found no difference betweenthree groups in terms of DLCO (p=0.947).Conclusion: The results of the study indicate that as microvascular complications(microalbuminuria) develop in the kidneys, possibly no microvascular changes occur in thelungs, if any, the changes do not cause any functional changes in type 2 diabetes mellitus patientsat early stages

Özet

Amaç: Mikroalbüminüri mikrovasküler değişikliklerin önemli bir göstergesidir. Bu aşamadahastaları yakalayabilmek kritik öneme sahiptir, çünkü agresif kan glukozu kontrolü ile nefropatien azından kısmi olarak geri döndürülebilmektedir. Bu bilgilerin ışığında böbreklerdemikroalbüminüri gelişmeden akciğerlerde mikrovasküler değişikliklerin olup olmadığınıaraştırmayı hedefledik.Materyal ve Metod: Bu amaçla normoalbüminürik ve mikroalbüminürik tip 2 diyabethastalarında karbonmonoksit difüzyon kapasitesini (DLCO) değerlendirdik. Yaş ve cinsiyetuyumlu 40 mikroalbüminürik, 40 normoalbüminürik tip 2 diyabet hastası ve 40 sağlıklı kontrolçalışmaya dahil edildi.Bulgular: Bu gruplar arasında DLCO sonuçlarını karşılaştırdık. Gruplar arasında DLCOölçümleri yönünden bir farklılık saptamadık (p=0,947).Sonuç: Bu çalışma mikrovasküler komplikasyonların geliştiği süreçte muhtemelen akciğerlerdevasküler değişikliklerin ortaya çıkmadığını göstermektedir. Eğer herhangi bir değişiklikoluşuyorsa da bu değişiklikler diyabet hastalarının akciğerlerinde fonskiyonel bozulmalara yolaçmamaktadır

🔖

Cite This Article

ÇELİK, Y., EREN, M. A., DAĞ, O. F., GENCER, M., ÇELİK, H., AKSOY, N., BÜYÜKHATİPOGLU, H. (2011). The Association Between Microalbuminuria and Carbonmonoxide Diffusion Capacity in Patients with Type-II Diabetes Mellitus. Düzce Tıp Fakültesi Dergisi, Cilt: 13 - Sayı: 2, 30–35. https://ajindex.com/articles/420492

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Narayan KM, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF: Lifetime risk for diabetes mellitus in the United States. JAMA. 290: 1884-1890, 2003. Budzikowski A: Obesity, diabetes and hypertension: a growing epidemic. Cardiol Rev 20: 9-10, 2003. Boden G: Pathogenesis of type 2 diabetes: insulin resistance. Endocrinol Metab Clin North Am. 30: 801-815, 2001.
  2. Schmidt AM, Yan SD, Wautier JL, et al: Activation of receptor for advanced glycation end products: a mechanism for advanced dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res. 84: 489-497, 1999.
  3. Lu M, Kuroki M, Amano S, et al: Advanced glycation end products increase retinal vascular endothelial growth factor expression. J Clin Invest. 101: 1219-1224, 1998.
  4. Creager MA, Lüscher TF, Cosentino F, et al: Diabetes and vascular disease: pathophysiology, clinical consequences and medical therapy: Part I. Circulation 2003; 108: 1527-1532, 2003.
  5. Kodolova IM, Lysenko IV, Saltykov BB: Change in the lung in diabetes mellitus. Arkh Pathol. 44: 35-40, 1982.
  6. Kida K, Utsuyama M, Takizawa T, Thurlbeck WM: Changes in lung morphologic features and elasticity caused by streptozotocin-induced diabetes mellitus in growing rats. Am Rev Respir Dis. 128: 125-131, 1983.
  7. Vracko R, Thorning D, Huang TW: Basal lamina of alveolar epithelium and capillaries: quantitative changes with aging and in diabetes mellitus. Am Rev Respir Dis. 120: 973-983, 1973.
  8. Crapo RO, Jensen RL, Wanger JS: Single-breath carbon monoxide diffusing capacity. Clin Chest Med. 22:637-49, 2001. Demir T: Difüzyon testi. Akciğer Fonksiyon Testleri Fizyolojiden KlinikUygulamaya Kitabında. Yıldırım N (editör). Turgut Yayıncılık ve Ticaret A.Ş. pp: 146-153, 2004. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 352:837-53, 1998.
  9. Caner B, Ugur O, Bayraktar M, et al: Impaired lung epithelial permeability in diabetics detected by technetium-99m-DTPA aerosol scintig-raphy. J Nucl Med. 35:204-6, 1994.
  10. Lange P, Groth S, Mortensen J, et al: Diabetes mellitus and ventilatory capacity:a five year follow-up study. Eur Respir J. 3:288-92, 1990.
  11. Turaçlar UT, Candan F, Sümer H: Tip 2 diyabetik hastalarda solunum fonksiyon testleri. Tüberküloz ve Toraks Dergisi. 47:54-7, 1999.
  12. Primhak RA, Whincup G, Tsanakas JN, Milner RDG: Reduced vitalcapacity in insulin dependent diabetes. Diabetes. 1987;3